← ANALYST RATINGS · TIPRANKS
NovoCure (NVCR): analyst forecast and price target
Analyst consensus
Hold0 Buy1 Hold0 Sell
Ratings of 1 analysts in the last 3 months · top analysts only12-month forecast
Based on 1 price targets given in the last 3 months, the average target is $20.00, the highest $20.00, the lowest $20.00. The average is +42.1% from the last price of $14.07.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $14.00 → $14.50+3.6% | Hold | +3.1% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $13.50 → $14.00+3.7% | Hold | −0.5% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $14.50 → $15.00+3.4% | Hold | +6.6% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $14.00 → $14.50+3.6% | Hold | +3.1% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $14.50 → $14.00−3.4% | Hold | −0.5% | Reiterated | 15.10.26on TipRanks 13:05 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $14.50 → $14.00−3.4% | Hold | −0.5% | Reiterated | 15.10.26on TipRanks 13:05 | — | |
| Jason Bednar★★★★★★★★★★#11450 · hits 46% · avg −2.5% | Piper Sandler | $29.00 | Buy | +106.1% | Reiterated | 24.07.26on TipRanks Jul 27 08:46 | −11.8%next day −3.5% · 5 days −17.0% | ↗ |
| David Nierengarten★★★★★★★★★★#297 · hits 55% · avg +23.0% | Wedbush | $18.00 → $20.00+11.1% | Hold | +42.1% | Reiterated | 24.07.26on TipRanks 07:56 | −11.8%next day −3.5% · 5 days −17.0% | ↗ |
| Emily Bodnar★★★★★★★★★★#2140 · hits 39% · avg +7.2% | H.C. Wainwright | $52.00 | Buy | +269.6% | Assigned | 24.07.26on TipRanks 07:56 | −11.8%next day −3.5% · 5 days −17.0% | ↗ |
| Jessica Fye★★★★★★★★★★#1182 · hits 56% · avg +9.4% | J.P. Morgan | $17.00 | Hold | +20.8% | Reiterated | 13.07.26on TipRanks 05:55 | −0.5%next day −3.7% · 5 days 0.0% | ↗ |
| Larry Biegelsen★★★★★★★★★★#2729 · hits 53% · avg +3.8% | Wells Fargo | $13.50 → $17.00+25.9% | Hold | +20.8% | Assigned | 04.05.26on TipRanks 06:40 | +2.2%next day −7.0% · 5 days +3.9% | ↗ |
| Vijay Kumar★★★★★★★★★★#2375 · hits 54% · avg +4.8% | Evercore ISI | $16.00 → $20.00+25.0% | Buy | +42.1% | Reiterated | 01.05.26on TipRanks 08:20 | +9.0%next day +2.2% · 5 days +5.3% | ↗ |
| Unknown Analyst | Ladenburg Thalmann & Co. | $27.00 | Buy | +91.9% | Reiterated | 27.02.26on TipRanks 19:46 | −1.2%next day −0.7% · 5 days −3.3% | ↗ |
| Jonathan Chang★★★★★★★★★★#2398 · hits 37% · avg +7.3% | Leerink Partners | $24.00 | Buy | +70.6% | Reiterated | 13.01.26on TipRanks 09:21 | −3.5%next day +1.4% · 5 days +0.5% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering NovoCure
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $29.50 at a price of $15.95 (+85.0%); now: $33.67 at $14.07 (+139.3%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 0 | 0 | 0 |
| Hold | 1 | 3 | 5 | 4 | 2 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.23 (from $-0.31 to $-0.14). Last quarter: $-0.13.
Sales
Next quarter’s sales estimate — $182M (from $180M to $187M). Last quarter: $184M.
Best top-analyst consensus in the sector · Healthcare
About NovoCure
- CEO: Frank Leonard
- Employees: 1,605
- Neuhofstrasse 21, Baar, 6340, CH
- www.novocure.com
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Data from the stock’s TipRanks forecast page, read 172 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗